Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-β treatment are predictive of long-term therapeutic response

Journal of Interferon and Cytokine Research

Volumn 22, Issue 3, 2002, Pages 389-395

  Enomoto, Masaru ^a   Nishiguchi, Shuhei ^a   Tanaka, Motoharu ^a   Fukuda, Katsuhiko ^a   Ueda, Tadashi ^a   Tamori, Akihiro ^a   Habu, Daiki ^a   Takeda, Tadashi ^a   Shiomi, Susumu ^a   Yano, Yoshihisa ^a   Otani, Shuzo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; GENETICS; KINETICS; METHODOLOGY; MIDDLE AGED; MONITORING; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; TIME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COMPARATIVE STUDY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; INTERFERON-BETA; KINETICS; MALE; MIDDLE AGE; MONITORING, PHYSIOLOGIC; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0036013768     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999002753675820     Document Type: Article

References (30)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report
3. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
4. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
5. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial
6. Treatment of chronic non-A non-B hepatitis with human interferon beta: A preliminary study
7. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
8. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta
9. Real-time detection system for quantification of hepatitis C virus genome
10. Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus
11. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
12. Dynamics of hepatitis C viremia following interferon-α administration
13. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reactions as a predictor of long-term response to interferon alpha treatment
14. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta
15. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta
16. Detection of hepatitis C virus antibody in the absence of viral RNA in patients with autoimmune hepatitis
17. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
18. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
19. Classification of chronic hepatitis: Diagnosis, grading, and staging
20. Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein
21. Clinical pharmacokinetics of interferons
22. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy
23. HCV genotypes in chronic hepatitis C and response to interferon
24. Interferon-alpha for chronic hepatitis C: An analysis of pretreatment clinical predictors of response
25. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronica hepatitis C
26. Efficacy of the combination therapy using twice-a-day IFN-beta followed by IFN alpha-2b in treatment for chronic hepatitis C
27. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C
28. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen
29. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C
30. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C